Back to Search
Start Over
Long-term adverse events, efficacy, and tolerability of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin in patients aged
- Source :
- Revista Alergia México, Vol 65 suppl 1, Pp 124-125 (2018)
- Publication Year :
- 2018
- Publisher :
- Colegio Mexicano de Inmunología Clínica y Alergia, A.C., 2018.
-
Abstract
- Background: Recombinant human hyaluronidase (rHuPH20)-facilitated subcutaneous infusion of immunoglobulin (fSCIG; HyQvia) is a new Ig treatment combining the advantages of intravenously and conventional subcutaneously-administered immunoglobulin (Ig) with infusion at rates, volumes and frequencies similar to intravenous Ig (IVIG), and favorable systemic tolerability. Objectives: We report the efficacy, adverse events, and tolerability of fSCIG in patients aged
Details
- Language :
- English, Spanish; Castilian
- ISSN :
- 00025151 and 24489190
- Volume :
- 65 suppl 1
- Database :
- Directory of Open Access Journals
- Journal :
- Revista Alergia México
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.6f99c4bf23f2402fa8797e8efe839702
- Document Type :
- article